Genentech: Shion Lim | Principal Scientist, Antibody Engineering, Drug Discovery

Scientists / Our Scientists

"It’s very fulfilling to work at a place like Genentech where I am constantly inspired to grow and innovate."

Years at Genentech

Awards & Honors

I joined the Antibody Engineering Department at Genentech in 2020 after completing my postdoctoral work at UCSF where I investigated antibody-based strategies to target disease-specific neo-epitopes. Prior to this, I completed my graduate studies at UC Berkeley in protein biophysics.

I was drawn to Genentech because I wanted to be part of a scientific community with a strong commitment and proven track-record for delivering life-changing medicines for patients. I feel incredibly fortunate to collaborate with talented colleagues across the organization to discover and engineer the next generation of biotherapeutics.

Featured Publication

Engineering interferons and interleukins for cancer immunotherapy.

2022, Advanced Drug Delivery Reviews, 182, 114112.

Holder PG*, Lim SA*, Huang CS, Sharma P, Dagdas Y, Bulutoglu B, Sockolosky JT.

View Abstract

Targeting a proteolytic neoepitope on CUB domain containing protein 1 (CDCP1) in RAS-driven cancers.

2022, Journal of Clinical Investigation, 132, e154604.

Lim SA*, Zhou J*, Martinko AJ, Wang YH, Filippova EV, Steri V, Wang D, Remesh SG, Liu J, Hann B, Kossiakoff AA, Evans MJ, Leung KK, Wells JA.

View Abstract

My group is interested in discovering and engineering novel antibody and protein-based molecules to enable the next generation of biotherapeutics and biological tools. We are interested in expanding beyond the traditional antibody scaffold and building novel functionalities and mechanisms of actions into these molecules. By doing so, we hope to expand the targetable space, enable exquisite specificity for safer and more effective therapies, and endow molecules with unique properties to address limitations of existing drugs. We are also excited about leveraging AI/ML and computational tools to accelerate the drug discovery process. The projects in my group require active collaboration with researchers across Large Molecule Drug Discovery, the various Therapeutic Areas, and throughout the research organization.

University of California, Berkeley, Ph.D. in Molecular and Cell Biology – 2018
Massachusetts Institute of Technology, B.S. in Chemistry and Biology – 2012

Alan J. Bearden Award for Outstanding Dissertation in Biophysics – 2018
Helen Hay Whitney Postdoctoral Fellowship – 2018
National Science Foundation Graduate Research Fellowship – 2013
Massachusetts Institute of Technology F.D. Greene Chemistry Award – 2012

Attention: This page may not render properly. The browser you are using, Internet Explorer 10, is no longer supported.

Shion Lim

Principal Scientist, Antibody Engineering, Drug Discovery

Featured Publication

Engineering interferons and interleukins for cancer immunotherapy.

Targeting a proteolytic neoepitope on CUB domain containing protein 1 (CDCP1) in RAS-driven cancers.